Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor
Authors
Keywords
-
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-04-28
DOI
10.1007/s00432-023-04806-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors
- (2023) Ziyi He et al. Translational Lung Cancer Research
- Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor
- (2022) Yuki Shinno et al. Clinical Lung Cancer
- Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors
- (2022) Justine Gantzer et al. ONCOLOGIST
- SMARCA4 ‐deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: A case report
- (2022) Takahiro Utsumi et al. Thoracic Cancer
- TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy
- (2022) Jiangyong Yu et al. Cancers
- Molecular, clinicopathological characteristics and surgical results of resectable SMARCA4-deficient thoracic tumors
- (2022) Jizhuang Luo et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- SMARCA4: Current status and future perspectives in non-small-cell lung cancer
- (2022) Yumeng Tian et al. CANCER LETTERS
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- (2021) Luis Paz-Ares et al. LANCET ONCOLOGY
- Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy
- (2021) Marek Wanior et al. ONCOGENE
- Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma
- (2021) Hayato Kawachi et al. Immunotherapy
- SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
- (2021) Joao V. Alessi et al. Journal of Thoracic Oncology
- SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy
- (2021) Kristina Mardinian et al. MOLECULAR CANCER THERAPEUTICS
- The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
- (2021) Andrew G. Nicholson et al. Journal of Thoracic Oncology
- Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report
- (2020) Yuki Iijima et al. Immunotherapy
- Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
- (2019) K M Heinhuis et al. ANNALS OF ONCOLOGY
- Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor
- (2019) C Henon et al. ANNALS OF ONCOLOGY
- Thoracic SMARCA4-deficient sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas
- (2019) N. Rekhtman et al. Journal of Thoracic Oncology
- Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report
- (2019) Kohichi Takada et al. Thoracic Cancer
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- SMARCA4-deficient Thoracic Sarcomas
- (2018) Raul Perret et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
- (2017) Christian Manegold et al. Journal of Thoracic Oncology
- Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities
- (2017) Akihiko Yoshida et al. MODERN PATHOLOGY
- SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior
- (2017) Jennifer L Sauter et al. MODERN PATHOLOGY
- SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
- (2015) Francois Le Loarer et al. NATURE GENETICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started